WA-ITRON
14.2.2024 14:46:26 CET | Business Wire | Press release
Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today announced a new brand identity reflecting the company’s evolution and a new era of delivering enhanced intelligence to create a more resourceful world. The new brand identity reflects Itron’s commitment to creating new efficiencies, connecting communities, encouraging sustainability and increasing resourcefulness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214395189/en/
“Itron stands at the forefront of a rapidly changing world where the challenges of energy and water scarcity, escalating demand and enabling the energy transition are more pressing than ever,” said Tom Deitrich, Itron’s president and CEO. “Our new brand identity honors our history and reflects the company we have become while demonstrating our industry leadership and dedication to understanding and solving our customers' evolving needs.”
As a proven leader of the Industrial Internet of Things (IIoT) with one of the largest connected platforms and installed bases in the energy, water and smart city sectors, Itron is providing more intelligence at the grid edge and driving a smoother transition to cleaner energy and water delivery while transforming the way grid operators address critical challenges. Itron invents new ways for cities and utilities to work together so they can cost-effectively leverage the same intelligent grid edge infrastructure to deliver multiple services and applications on a reliable, resilient network capable of serving all stakeholders.
This new brand identity serves as a strategic move for Itron as the company expands its offerings, signaling to the market the company’s evolution and growth in several key focus areas:
- Electricity: Enabling improved visibility and control at the grid edge. Boosting utility and city customers’ energy efficiency and cost savings and enabling the transition to lower-carbon energy, EVs and a more robust, resilient and reliable grid.
- Water: Safeguarding the water supply, finding leaks, reducing waste and improving safety.
- Smart Cities: Connecting, protecting and unlocking endless possibilities for more sustainable, thriving communities.
- Gas: Ensuring safety and integrity in the natural gas delivery system while unlocking more insights from that same system than ever before.
- Sustainability: Leaving a legacy of responsible energy and water management and reducing both Itron’s and its customers’ carbon footprint.
As part of the refreshed brand identity, Itron is introducing a more modern logo that showcases a leaner font, a more upright design, more modern lines and richer, deeper colors. The ray or beam of light shining out from the ‘O’ symbolizes Itron’s leadership and ability to light the way forward for the industry.
“At Itron, we are a catalyst for positive change, delivering intelligent, secure and reliable solutions that power homes, ensure the delivery of clean water and contribute to well-lit and safer streets, enabling a brighter, more sustainable future,” said Marina Donovan, Itron’s vice president of global marketing, ESG and public affairs. “Our new brand identity reflects and projects our edge intelligence offerings and a new era for Itron.”
For more details on Itron’s new brand identity, see the Itron Press Kit, which features brand guidelines, logo files and updated fact sheet and watch the brand history video. Also visit Itron at DISTRIBUTECH International, Feb. 27-29, 2024, in booth #2200 where the new brand will be on full display.
About Itron
Itron is a proven global leader in energy, water, smart city, IIoT and intelligent infrastructure services. For utilities, cities and society, we build innovative systems, create new efficiencies, connect communities, encourage conservation and increase resourcefulness. By safeguarding our invaluable natural resources today and tomorrow, we improve the quality of life for people around the world. Join us: www.itron.com.
Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.
Additional Resources
- LinkedIn: https://www.linkedin.com/company/itroninc/
- X: https://twitter.com/ItronInc
- Newsroom: www.itron.com/company/newsroom
- Blog: https://blogs.itron.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214395189/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
